AIAI
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
AIAI Holdings Corporation Class A Common Stock
- Nom
- AIAI Holdings Corporation Class A Common Stock
- Secteur
- Industrials
- Industrie
- Conglomerates
- Bourse
- NASDAQ
- Capitalisation
- $144.9M
- Employés
- 18
- PDG
- Todd A. Furniss
- Site web
- https://www.aiaiholdings.com
- Marché
- —
AIAI Holdings Corporation, an enterprise founded in Dallas, Texas in 2024, is dedicated to developing an advanced, AI-powered business ecosystem. Its strategy involves the strategic acquisition and global expansion of various companies. The firm leverages its exclusive artificial intelligence platform to substantially boost the operational efficiency of the entities within its diverse investment portfolio. These holdings span a broad spectrum of industries, including construction, healthcare, defense, infrastructure for blockchain data, digital financial instruments, and public sector operations. The company was previously known as MXLII Corporation, undergoing a name change to AIAI Holdings Corporation in November 2025.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 48 762 titres (~184 605,50 $ US)
- Insiders
- Affeldt EricRemy Donald Michael
- Total bought
-
$184,606
Avg buy (VWAP, 90d window) $4.44 vs last close $1.84 (-58.6%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-22
- Liquidity
- Illiquid $628,975/day · 20d vol
- Last synced
-
2026-10-23 21:10:04
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-22 | Affeldt Eric | Buy · P | 42,857 | $3.50 | $150,000 | Form 4 |
| 2026-08-24 | Carlton Charles Craig | Buy · P | 8,250 | $6.09 | $50,242 | Form 4 |
| 2026-08-21 | Carlton Charles Craig | Buy · P | 7,250 | $6.83 | $49,518 | Form 4 |
| 2026-08-20 | Remy Donald Michael | Buy · P | 365 | $5.40 | $1,971 | Form 4 |
| 2026-08-19 | Remy Donald Michael | Buy · P | 540 | $5.25 | $2,835 | Form 4 |
| 2026-08-19 | Affeldt Eric | Buy · P | 5,000 | $5.96 | $29,800 | Form 4 |
| 2026-08-19 | Furniss Todd Anthony | Buy · P | 1,000 | $5.59 | $5,590 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
AIAI presents a compelling event-driven catalyst — a high-profile M&A LOI targeting a defense asset with $250M projected FCF, backed by significant insider and strategic accumulation — but the complete absence of…
The first sentence of the analysis written for AIAI on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. No liquidity or margin figures stored
Suggested stop 1.31, 1.5 ATR under the last close(28.9% under the last close). Reward/risk to the next stored resistance is 4.57. Research, not advice. Not an order.
Recent news
- 2026-10-14 AIAI Holdings to Present at the 20th Annual LD Micro Main Event DALLAS, TX / ACCESS Newswire / October 14, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI to enhance portfolio performance, today announced that Chief Executive Officer Todd Furniss will present at the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. AIAI Holdings is scheduled to present on Wednesday, October 21, 2026 at 02:30 PM PT.
- 2026-10-08 Rochon Family Executes Additional Strategic Purchase of $26.8 Million of AIAI Holdings Shares DALLAS, TX / ACCESS Newswire / October 8, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI to enhance portfolio performance, today announced that certain entities controlled by the family of John P. Rochon have acquired approximately $26.8 million of Ai² shares through privately negotiated transactions with an existing large stockholder.
- 2026-10-07 NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright''s AI-Based Drug Discovery and Development Conference TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that Dr. Joseph Geraci, Founder and Chief Scientific and Technical Officer, will participate in the H.C. Wainwright 3rd Annual AI Based Drug Discovery and Development Virtual Conference, taking place October 8–9, 2026.
- 2026-09-18 AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement Capital Contribution Requires no Consideration to be Paid DALLAS, TX / ACCESS Newswire / September 18, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its affiliated entity, Messier 42 LLC ("M42"), has agreed to contribute to the capital of the Company a controlling position in the entity holding M42''s marketing agreement for the sale of military equipment (the "Teaming Agreement"). Under this arrangement, 100% of the revenue and EBITDA generated by the M42 entity which holds the Teaming Agreement will be consolidated on the Company''s financial statements and reported by the Company and the Company will distribute approximately 50% of the resulting Free Cash Flow to M42.
- 2026-09-17 AIAI Holdings'' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare Constellation Brings Dôr''s Retail Intelligence Architecture to Healthcare Connects Clinical, Scheduling, Call-Center and Staffing Data to Predict Care Needs, Optimize Provider Capacity and Improve Patient Access DALLAS, TX / ACCESS Newswire / September 17, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance announced today that its portfolio company, Constellation Network, through Dôr Technologies, has launched Dôr Patient Journey, a new healthcare intelligence platform. Developed in collaboration with Proactive MD, the platform is actively deployed within Proactive MD''s care environment.
- 2026-09-11 AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value DALLAS, TX / ACCESS Newswire / September 11, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance announced today that it has entered into amendments to its existing lock-up agreements entered into in connection with the Company''s direct listing with holders of the Company''s outstanding shares of Class A Common Stock. The list of those signing the amendment includes the Company''s founder and Chairman, other members of the Company''s board of directors, members of management and a majority of its largest stockholders.
- 2026-09-03 AIAI Holdings Announces Letter of Intent with Messier 42 LLC to Acquire Controlling Interest in Defense & National Security Company With Projected $250M of Annual Free Cash Flow Post Closing DALLAS, TX / ACCESS Newswire / September 3, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, announced that the Company has entered into a letter of intent with its affiliated entity, Messier 42 LLC ("M42"), to acquire a controlling interest in one of M42''s businesses with operations in the defense industry. M42 projects that this business is expected to produce $250 million in Free Cash Flow during the 12 months following the closing.
- 2026-09-01 NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, announced today the appointment of Dr. Keith M.
- 2026-08-24 AIAI Holdings Commences Discussions with Messier 42 LLC Regarding Acquisition Opportunities DALLAS, TX / ACCESS Newswire / August 24, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai2" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, announced today that, following discussions with its board, the Company is commencing discussions with Messier 42 LLC, a company controlled by our founder and controlling stockholder, John P. Rochon, to begin the process of acquiring a number of M42''s existing and targeted businesses across multiple sectors to help execute the Company''s vision, including international and domestic defense, intelligence, healthcare, gaming and rare earth minerals.
- 2026-08-20 NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and operational developments as the Company continues to advance adoption of its proprietary NetraAI platform across the pharmaceutical and clinical-research industries.
Market snapshot
Financial ratios
No ratio data synced.
Key metrics
No metrics data synced.
Employee count
No employee-count data synced.
Peer market caps
No peer data synced.